A CRRT apparatus comprising a filtration unit (2), a blood circuit (17), a blood pump (21), a dialysate line (13) and one or more lines (8; 51; 57; 58; 63; 69; 67; 74) to transfer a respective solution into blood; a fluid source for each of said one or more lines, wherein said solution comprises at least one buffer agent in the form of bicarbonate or bicarbonate precursor. A control unit (12) is configured to receive a patient prescription and to determine a parameter (J.sub.buffer_load/BW) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment, wherein said parameter is determined as a function of the concentration of said buffer agent in said fluid source and as a function of the estimated or calculated patient systemic steady state concentration of bicarbonate and/or bicarbonate precursors.

In some examples, a filtration assembly for hemodiafiltration therapy includes a filtration body connector configured to removably mechanically connect the filtration assembly and a dialyzer. In examples, the filtration assembly is configured to remain substantially stationary relative to the dialyzer when the filtration assembly mechanically mates with the dialyzer. The filtration body connector is configured to removably mechanically connect the filtration assembly with a plurality of different types of dialyzers, which may be selected based on a prescription for a particular patient.

A blood filtration system can reduce the amount of plasma constituents (e.g., water and/or electrolytes) in the blood of the patient, and accordingly increase the hematocrit value of the patient. The blood filtration system (e.g., a controller, or the like) can determine a hematocrit value of a patient. The blood filtration system can determine a venous pressure of vasculature of a patient. The blood filtration system can compensate for pressure head in a component of a blood circuit (e.g., a withdrawal line of a catheter), for example to improve the accuracy of the venous pressure determination. The blood filtration system can determine one or more resistance characteristics of a blood circuit for the blood filtration system. The resistance characteristics can correspond to a resistance to a flow of blood through a component of the blood circuit.

A dialysis fluid system includes a dialysis fluid inlet; a dialysis fluid outlet; a pump positioned and arranged to pump dialysis fluid through the dialysis fluid inlet and the dialysis fluid outlet; and an inductive heater located between the dialysis fluid inlet and the dialysis fluid outlet, the inductive heater including a fluid flowpath positioned and arranged to receive non-heated dialysis fluid from the dialysis fluid inlet and to output heated dialysis fluid to the a dialysis fluid outlet, a conductive heater element located within the fluid flowpath so as to be or act as a secondary coil of a transformer, and a primary coil of the transformer located outside of the fluid flowpath and positioned so as to magnetically induce a current into the conductive heater element, causing the conductive heater element and surrounding fluid to heat.

A peritoneal dialysis system includes a control unit is programmed to cause (i) a pressure sensor to take a first pressure reading of a reference chamber with a pneumatic valve closed, (ii) a pump actuator to pump fresh dialysis fluid through a fresh dialysis fluid pathway into a patient line expandable chamber, expanding the expandable chamber into a dome, (iii) the pneumatic valve to open, allowing the reference chamber to communicate pneumatically with any air in the dome, (iv) the pressure sensor to take a second pressure reading with the pneumatic valve open, (v) the first and second pressure readings to be used with the ideal gas law to determine an amount of air in the dome, and (vi) the amount of air in the dome and a known volume of the dome to be used to determine an amount of fresh dialysis fluid delivered into the expandable chamber.

Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (Aβ) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a Aβ displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds Aβ (for instance, Aβ peptide or non-plaque Aβ) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free Aβ peptide (for instance, Aβ monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free Aβ peptide in the periphery may ultimately lead to less Aβ peptide in the CNS, which may decrease Aβ plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.

A dialysis method to enable a patient to undergo both peritoneal dialysis and extracorporeal blood treatments is disclosed. The method includes determining, via a base unit controller, whether a peritoneal dialysis treatment or an extracorporeal blood treatment is to be performed. If the peritoneal dialysis treatment is to be performed, the method includes operating first software instructions that cause a base unit to use a first fluid stored in a fluid container. If the extracorporeal blood treatment is to be performed, the method includes operating second software instructions that cause the base unit to use a second, different fluid from an online source and selectively move the second, different fluid to a blood treatment unit for use in the extracorporeal blood treatment. The blood treatment unit is operable with the base unit to perform the extracorporeal blood treatment on a patient.

The present disclosure describes a device and method to clear solutes from a patient's blood while maintaining fluid balance. In some implementations, the device and method is used to assist the filtration functions of a patient's liver or kidney. The device includes a plurality of hollow fibers that pass through a sequence of alternating filtration chambers and infusion chambers. The filtration chambers filter the patient's blood while the infusion chambers rehydrate the filtered blood.

The invention relates to a blood line (108) comprising an infusion site (145) intended to inject into the line a solution, comprising: a first main channel (200) having a first passage section, a second main channel (220) having a second passage section, means for the formation (210) of a turbulence area located downstream from the first main channel, located upstream from the second main channel, these formation means comprising a first fluid passage means (224) defining a reduction (225) in the passage section and whose smallest passage section is smaller than the first passage section and smaller than the second fluid passage section, a secondary channel (230) comprising an inlet (231) for letting in the solution and an outlet (232) in fluid communication with the first main channel or the means for the formation of a turbulence area or the second main channel.

Methods and systems for providing continuous renal replacement therapy (CRRT) to a patient are provided. The system includes a hemofiltration unit that provides continuous venovenous hemofiltration (CVVH), a replacement fluid flow regulator configured to regulate the flow of a replacement fluid, an anticoagulant flow regulator configured to pump an anticoagulant, and a blood warmer. The system provides enhanced access to the extracorporeal circuit for blood analysion, infusion of products and/or anticoagulation control. The system may be used to treat patients having renal insufficiency.